Nektar Therapeutics (NKTR) Stock Price & Analysis
Nektar Therapeutics (NKTR) fell 0.69% to USD 56.23 as of June 10, 2026 at 08:36 UTC, according to Nexqual real-time market data.
NKTR last closed at USD 56.62; the session ranged USD 54.13–58.85 on volume of 1,153,851 shares. Market capitalization is $1.90B, with a 52-week range of USD 7.99–109 (NCM). Source: Nexqual, June 10, 2026 at 08:36 UTC.
Key Statistics (as of June 10, 2026 at 08:36 UTC)
| Price | USD 56.23 |
|---|---|
| Change | ▼ 0.69% (down) |
| Previous Close | USD 56.62 |
| Open | USD 57 |
| Day Range | USD 54.13 – 58.85 |
| 52-Week Range | USD 7.99 – 109 |
| Volume | 1,153,851 shares |
| Market Cap | $1.90B |
| Exchange | NCM |
Technical Analysis (NKTR)
Nexqual's technical model rates NKTR "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 12.1 (oversold) |
| vs SMA50 | Below (USD 76.19) |
| MACD | -5.69 (negative) |
Analyst Ratings (NKTR)
Wall Street analysts rate NKTR "Strong Buy" based on 8 analysts, with a mean price target of USD 153.25 (range USD 80–192), per Nexqual as of June 10, 2026 at 08:36 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 153.25 |
| High Target | USD 192 |
| Low Target | USD 80 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (NKTR)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -2.04 |
| Revenue Estimate | $10.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.78 vs est -1.48 ▼ miss |
| 2025-12-31 | USD -1.29 vs est -3.5 ▲ beat |
| 2025-09-30 | USD -1.87 vs est -2.79 ▲ beat |
| 2025-06-30 | USD -2.78 vs est -3.12 ▲ beat |
Source: Nexqual, June 10, 2026 at 08:36 UTC.
Financials & Fundamentals (NKTR)
| Total Revenue | $55.63M |
|---|---|
| Revenue Growth (YoY) | +3.80% |
| Gross Margin | +100.00% |
| Operating Margin | -352.25% |
| Profit Margin | -284.18% |
| ROE | -53.60% |
| Debt / Equity | 24.89 |
| Current Ratio | 10.21 |
| Total Cash | $568.60M |
| Total Debt | $143.43M |
| Free Cash Flow | $-107.23M |
Source: Nexqual, June 10, 2026 at 08:36 UTC.
Financial Health Score (NKTR)
Nexqual rates Nektar Therapeutics's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:36 UTC.
| Growth | Critical — Revenue -44% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $569M cash vs $143M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$107M, burning cash |
| Efficiency | Critical — ROE -54%, ROA -15.3% |
Ownership (NKTR)
| Insider Ownership | +0.45% |
|---|---|
| Institutional Ownership | +79.98% |
| Shares Outstanding | 33.79M |
| Float | 29.11M |
| Short % of Float | +15.07% |
Source: Nexqual, June 10, 2026 at 08:36 UTC.
Leadership (NKTR)
Nektar Therapeutics is led by Howard W. Robin (age 72), CEO, President & Director, per Nexqual as of June 10, 2026 at 08:36 UTC.
| CEO, President & Director | Howard W. Robin (age 72) |
|---|---|
| CFO and Principal Financial & Accounting Officer | Linda M. Rubinstein M.A. (age 58) |
| Senior Vice President of Biologics Process Development & Manufacturing | Ken Franke |
| Senior Vice President of Clinical Development Operations | Charleen Jue |
Major Backers & Investors (NKTR)
Notable institutional backers of Nektar Therapeutics include FMR, LLC, Fidelity, BVF Inc., according to Nexqual as of June 10, 2026 at 08:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 12.74% |
| Fidelity | 8.43% |
| BVF Inc. | 7.58% |
| Two Seas Capital Lp | 5.8% |
| Two Sigma Investments, LP | 2.75% |
| Prosight Management, Lp | 2.18% |
| Morgan Stanley | 1.95% |
| Armistice Capital, LLC | 1.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7% |
| BlackRock | 2.05% |
Source: Nexqual, June 10, 2026 at 08:36 UTC.
From Nektar Therapeutics's Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
- It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
- It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
- Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALKS | Alkermes plc | USD 44.29 | ▲ 3.48% |
| NBIX | Neurocrine Biosciences, Inc. | USD 165.24 | ▲ 0.83% |
| SGMO | Sangamo Therapeutics, Inc. | USD 0.15 | ▼ 34% |
| INCY | Incyte Corporation | USD 103.23 | ▲ 0.83% |
| EXEL | Exelixis, Inc. | USD 52.99 | ▲ 0.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:36 UTC. This page is informational and not investment advice.